TY  - JOUR
T1  - The Role of Ocrelizumab in Multiple Sclerosis Treatment; Literature Review
A1  - Rawan Hamdan Alenazy
A1  - Mohammed Majed S Abualshamat
A1  - Fahad Sh S Dh Alqahs
A1  - Abdullah F N Almutairi
A1  - Mohammed Khalid Moslih Alharbi
A1  - Bandar Mohammad Alkhuraimi
A1  - Yahya Abdulrahman Dhamiri
A1  - Mohammed Munir Abdullah Alshahrani
A1  - Kholoud Mesfer Alshahrani
A1  - Mohammed Abdullah Alghamdi
A1  - Reham Khaleef Alenezi
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2021
VL  - 12
IS  - 3
DO  - 10.51847/y9PZJHl1Gk
SP  - 117
EP  - 120
N2  - Multiple sclerosis is a common leading cause of disability worldwide. CD20-expressing B cells play a major role in multiple sclerosis pathogenesis. Hence, anti-CD20 monoclonal antibodies effectively deplete B cells mainly by complement-dependent cytotoxicity, antibody-dependent cell-mediated phagocytosis, and antibody-dependent cellular cytotoxicity. While the precise etiology remains unknown, it is now recognized that environmental factors, such as smoking, vitamin D deficiency, Ebstein-Barr virus (EBV) infection, adolescent obesity, and sedentary lifestyle in addition to certain genes that are involved in disease progression. This literature reviews the current data supporting the efficacy and safety of ocrelizumab in the multiple sclerosis population. Relevant articles to the topic were searched in the PubMed database. The MeSh words were used are multiple sclerosis, anti-CD20 monoclonal antibodies, and ocrelizumab. Anti-CD20 monoclonal antibodies, particularly ocrelizumab, have gained attention in this targeted population. Based on the currently available data, ocrelizumab seems effective in B cells depletion and provides favorable outcomes in multiple sclerosis patients. Nevertheless, although most reported adverse events are infusion-related, several reported serious infections were reported in response to ocrelizumab infusion. 
UR  - https://archivepp.com/article/the-role-of-ocrelizumab-in-multiple-sclerosis-treatment-hzlqzasmtflciqa
ER  -